Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.58 |
| ▸ | CA1 | P00915 | 13/20 | 0.58 |
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23343670 | 0.82 | CA2 (0.61) | CA2CA1CA12CA9CA7 | |
| SCHEMBL14959419 | 0.80 | CA2 (0.63) | CA2CA1CA12CA9CA7 | |
| SCHEMBL24257976 | 0.78 | CA2 (0.54) | CA2CA1CA12CA9CA7 | |
| SCHEMBL8260632 | 0.77 | CA2 (0.63) | CA2CA1CA12CA9CA7 | |
| SCHEMBL23987219 | 0.76 | CA2 (0.58) | CA2CA1CA12CA9CA7 | |
| SCHEMBL13233461 | 0.76 | GPR35 (0.64) | CA2CA1CA12CA9CA4 | |
| SCHEMBL26801114 | 0.74 | CA2 (0.47) | CA2CA1CA12CA9CA7 | |
| SCHEMBL429778 | 0.74 | CA2 (1.00) | CA2CA1CA12CA9CA7 | |
| SCHEMBL14498996 | 0.74 | CYP1A2 (0.46) | SMN1; SMN2 | |
| SCHEMBL12021287 | 0.74 | TAAR1 (0.46) | CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | HEPANOVA, INC. (US) | 2021-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | AADAC, GOT2, ABAT | CA2 4761/4885CA1 4872/4885CA12 4666/4885 |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | CA2 4761/4885CA1 4872/4885CA12 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.